TW200515917A - Methods and compositions for the generation of a protective immune response against SARS-COV - Google Patents

Methods and compositions for the generation of a protective immune response against SARS-COV

Info

Publication number
TW200515917A
TW200515917A TW093127725A TW93127725A TW200515917A TW 200515917 A TW200515917 A TW 200515917A TW 093127725 A TW093127725 A TW 093127725A TW 93127725 A TW93127725 A TW 93127725A TW 200515917 A TW200515917 A TW 200515917A
Authority
TW
Taiwan
Prior art keywords
cov
compositions
generation
immune response
protective immune
Prior art date
Application number
TW093127725A
Other languages
Chinese (zh)
Inventor
Gary J Nabel
Wing-Pui Kong
Yue Huang
Zhi-Yong Yang
Original Assignee
Us Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Government filed Critical Us Government
Publication of TW200515917A publication Critical patent/TW200515917A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

The present invention relates to novel methods and compositions for the generation of a protective immune response in humans and other animals against the coronavirus responsible for Severe Acute Respiratory Syndrome (SARS-CoV).
TW093127725A 2003-09-15 2004-09-14 Methods and compositions for the generation of a protective immune response against SARS-COV TW200515917A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50350803P 2003-09-15 2003-09-15
US55031704P 2004-03-08 2004-03-08

Publications (1)

Publication Number Publication Date
TW200515917A true TW200515917A (en) 2005-05-16

Family

ID=34381075

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093127725A TW200515917A (en) 2003-09-15 2004-09-14 Methods and compositions for the generation of a protective immune response against SARS-COV

Country Status (2)

Country Link
TW (1) TW200515917A (en)
WO (1) WO2005027963A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113521269A (en) * 2020-04-22 2021-10-22 生物技术Rna制药有限公司 Coronavirus vaccine
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035556A2 (en) * 2003-05-06 2005-04-21 Iguazu Biosciences Corp. Sars-coronavirus virus-like particles and methods of use
WO2005012337A2 (en) * 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
WO2005060520A2 (en) * 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
WO2006071250A2 (en) * 2004-04-05 2006-07-06 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Soluble fragments of the sars-cov spike glycoprotein
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
US20230143215A1 (en) * 2020-04-23 2023-05-11 Isa Pharmaceuticals B.V. Immunization against sars-cov-related diseases
CN111505286A (en) * 2020-04-28 2020-08-07 郑州伊美诺生物技术有限公司 Novel coronavirus specific antibody double-antigen sandwich E L ISA detection kit and preparation method thereof
WO2021231659A1 (en) * 2020-05-12 2021-11-18 Sapphire Biotech, Inc. Neutralizing antibody testing and treatment
US11129890B1 (en) * 2020-05-19 2021-09-28 Vigene Biosciences, Inc. Non-integrating HIV-1 comprising mutant RT/IN proteins and the SARS-CoV-2 spike protein
CN112999333A (en) * 2021-02-04 2021-06-22 安域生物制药(杭州)有限公司 Application of multi-target blocking peptide in preventing and treating new coronavirus infection
CN117265014A (en) * 2021-05-25 2023-12-22 安徽省立医院(中国科学技术大学附属第一医院) Construction method and application of virus S protein mutant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2828405B1 (en) * 2001-08-09 2005-06-24 Virbac Sa ANTI-CORONAVIRUS VACCINE
NZ543467A (en) * 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
CN1449826A (en) * 2003-05-27 2003-10-22 武汉大学 Gene vaccine for anti SARS coronal virus and use thereof
CN1449831A (en) * 2003-06-03 2003-10-22 中国人民解放军第二军医大学 DNA vaccine pVPS2 for SARS virus
CN1185011C (en) * 2003-06-03 2005-01-19 中国人民解放军第二军医大学 DNA vaccine pVPS for SARS virus
WO2005005596A2 (en) * 2003-06-18 2005-01-20 Chinese National Human Genome Center At Shanghai Characterization of the earliest stages of the severe acute respiratory syndrome (sars) virus and uses thereof
WO2005010034A1 (en) * 2003-07-21 2005-02-03 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Soluble fragments of the sars-cov spike glycoprotein

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113521269A (en) * 2020-04-22 2021-10-22 生物技术Rna制药有限公司 Coronavirus vaccine
US11779659B2 (en) 2020-04-22 2023-10-10 BioNTech SE RNA constructs and uses thereof
US11925694B2 (en) 2020-04-22 2024-03-12 BioNTech SE Coronavirus vaccine
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine

Also Published As

Publication number Publication date
WO2005027963A2 (en) 2005-03-31
WO2005027963A3 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
MX2007003078A (en) Imidazoquinoline compounds.
AU2002360488A8 (en) Methods and devices for detection and therapy of atheromatous plaque
TWI369981B (en) Hmb compositions and uses thereof
TW200515917A (en) Methods and compositions for the generation of a protective immune response against SARS-COV
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
AU2008243079A1 (en) Compositions and methods for generating an immune response
ATE289640T1 (en) AMIDOFUNCTIONAL AMINOPOLYDIORGANOSILOXANES
TW200603825A (en) Prrsv subunit vaccines
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2007109812A3 (en) Immunopotentiating compounds
DK1377280T3 (en) Fillers as sense of satiety
EP1706146A4 (en) Nutrient compositions and methods for enhanced effectiveness of the immune system
MY143677A (en) Amide prodrug of gemcitabine, compositions and use thereof
MEP10209A (en) Stable emulsion composition
PL1965809T3 (en) Compositions to improve gut health and animal performance comprising beta-glucans and alfa-fucans
WO2007056142A3 (en) Methods of preventing the serotonin syndrome and compositions for use therefor
NO20073026L (en) 2-Alkoxy-3,4,5-trihydroxyalkylamides, preparation and compositions thereof, and use thereof
ECSP045493A (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLIBANSERINE POLYMORPH A
MX2007006042A (en) Bengamides with a substituted caprolactame cycle, method for the preparation thereof, compositions containing them and use thereof.
WO2004069173A3 (en) Methods for modulating an inflammatory response
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
DK1217898T3 (en) Hard caramels with improved storage stability
TW200706173A (en) Oral composition comprising carbamylating agent
WO2006102126A3 (en) Inhibitors of isoprenylcysteine carboxyl methyltransferase
MXPA05008131A (en) Methods for modulating an inflammatory response.